AdvaMedDx held a second briefing on Capitol Hill, "The Role of Advanced Diagnostics in Cancer Care", on September 20th. The briefing featured speakers who discussed how advanced diagnostics are delivering on the promise of personalized medicine by improving the ways we detect and treat cancer. The briefing drew over 70 attendees from Congressional offices, advocacy associations, provider groups, and press.
The panel discussion was moderated by AdvaMedDx Executive Director Andrew Fish.
To view the presentation, please click here.
To watch the briefing video, please view below or click here.
- Amalia M. Issa, PhD, MPH, Chair of the Department of Health Policy and Public Health and Director of the Program in Personalized Medicine and Targeted Therapeutics, University of the Sciences, gave a presentation on the science and application of personalized medicine in clinical practice, with regard to genomic medicine and how new molecular diagnostic tests are transforming cancer care.
- Cesar Garcia, President and CEO of IRIS International, presented a background on the NADIA ProsVue test. This innovative molecular prostate test was approved by the FDA in 2011. Mr. Garcia detailed how ProsVue is positively influencing decisions on follow-up care for the post-prostatectomy population (95,000 people a year in the United States), and noted that improvements to the regulatory and reimbursement systems are necessary to support and expedite the implementation of this kind of innovation throughout the diagnostics industry.
- Walter Koch, PhD, Vice President and Head of Global Research, Roche Diagnostics, presented on Roche's ZELBORAF™ and cobas® BRAF test co-development for late-stage melanoma patients. He discussed the improved value proposition molecular diagnostics offered to all involved stakeholder groups, as well as the challenges created by inconsistent regulatory requirements and oversight for manufacturers and investors.
- Marcia Horn, President & CEO of the International Cancer Advocacy Network, wrapped up the briefing with remarks on how molecular diagnostics are benefitting cancer patients.